2019 logo_150x35_jpg.jpg
Novan Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 14, 2022 07:00 ET | Novan, Inc.
– Rhofade prescriptions increased 37% for third quarter year-to-date from prior year – – Continued progress toward submission of berdazimer gel, 10.3% (SB206) New Drug Application (NDA), targeted...
2019 logo_150x35_jpg.jpg
Novan to Report Third Quarter 2022 Financial Results on November 14, 2022
November 07, 2022 09:00 ET | Novan, Inc.
DURHAM, N.C., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its third quarter 2022 financial results on Monday,...
2019 logo_150x35_jpg.jpg
EPI Health, a Novan Company, and MC2 Therapeutics Announce Data from Survey Conducted by National Psoriasis Foundation Presented at 42nd Annual Fall Clinical Dermatology Conference®
October 21, 2022 08:35 ET | Novan, Inc.
DURHAM, N.C. and COPENHAGEN, Denmark, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), EPI Health, a Novan Company, and MC2 Therapeutics today announced that...
2019 logo_150x35_jpg.jpg
EPI Health, a Novan Company, and MC2 Therapeutics Present New Data In Multiple Posters Highlighting WYNZORA’s® Unique PAD Technology™ at the 42nd Annual Fall Clinical Dermatology Conference®
October 21, 2022 08:35 ET | Novan, Inc.
DURHAM, N.C. and COPENHAGEN, Denmark, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), EPI Health, a Novan Company, and MC2 Therapeutics today announced...
2019 logo_150x35_jpg.jpg
Novan and EPI Health, a Novan Company, Announce Abstracts Accepted for Poster Presentation at the 42nd Annual Fall Clinical Dermatology Conference®
October 14, 2022 08:30 ET | Novan, Inc.
DURHAM, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN) and EPI Health, a Novan Company, today announced that eight abstracts have been accepted for...
2019 logo_150x35_jpg.jpg
EPI Health, a Novan Company, and MC2 Therapeutics Present WYNZORA® (calcipotriene and betamethasone dipropionate) Cream, 0.005%/0.064% Subgroup Data Analysis at Skin of Color Update 2022 Conference
September 15, 2022 08:00 ET | Novan, Inc.
– New data analysis from previously completed successful Phase 3 study1 demonstrated WYNZORA® Cream to be effective and convenient for skin of color patients for the treatment of plaque psoriasis ...
2019 logo_150x35_jpg.jpg
Novan Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 11, 2022 06:30 ET | Novan, Inc.
– Total revenue of $6.2 million for the second quarter 2022 – – Activities on track for submission of berdazimer gel, 10.3% (SB206) New Drug Application (NDA), targeting submission before the...
2019 logo_150x35_jpg.jpg
Novan to Report Second Quarter 2022 Financial Results on August 11, 2022
August 04, 2022 09:05 ET | Novan, Inc.
DURHAM, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its second quarter 2022 financial results on Thursday,...
2019 logo_150x35_jpg.jpg
Novan Satisfies $16.5 Million Outstanding Promissory Note
July 19, 2022 08:30 ET | Novan, Inc.
– Novan and Evening Post Group enter into a loan payoff and termination agreement, fully satisfying the promissory note and all related obligations – – Novan saves $11.1 million in principal and...
2019 logo_150x35_jpg.jpg
Novan Announces Closing of Approximately $15.0 Million Registered Direct Offering Priced At-the-Market
June 13, 2022 16:05 ET | Novan, Inc.
DURHAM, N.C., June 13, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the closing of the Company’s previously announced registered direct offering...